|
|
|
Home >
Health Condition > Alzheimer's Disease
> Aduhelm (aducanumab)
Aduhelm (aducanumab)
Related Topics:
News & Research:
-
Aducanumab for
Alzheimer's Gets Thumbs Down in Europe - Medscape, 12/17/21 -
"The EMA committee noted that while aducanumab
reduces amyloid beta in the brain, the link between this effect and clinical
improvement had not been established ... The committee also felt that
results of the main studies assessing the drug were "conflicting and did not
show overall that Aduhelm was effective at treating adults with early stage
Alzheimer's disease.""
-
Potential new treatment for Alzheimer’s disease would be relatively cheap
- 11/30/21 - "the researchers fed the model mice
with diazoxide -- a drug that activates the KATP channel -- and tested their
memory. They found that while the untreated Alzheimer's disease model mice
exhibited their characteristically poor memory, the treated model mice
performed just as well as normal mice. A look at the brains of the treated
mice showed that they lacked the hallmark Aβ plaques ... Our findings point
directly to a potential way of preventing and treating Alzheimer's disease
... On top of that, compared with Aβ-targeting immunotherapy, such as the
drug aducanumab, which was recently approved by the FDA, synthetic agonists
for the KATP channel are less expensive and would be more acceptable to
aging societies around the world" - Note: Aduhelm (aducanumab) is the one that costs $56,000 per year and is the reason Medicare
premiums went up. It reduces the amyloid β peptide but doesn't seem to
reduce Alzheimer's. Diazoxide sounds like it's got side-effects that
seniors don't want to mess with.
- Diazoxide -
Wiki - "Common side effects include high blood
sugar, fluid retention, low blood platelets, a fast heart rate,
increased hair growth, and nausea.[2] Other severe side effects include
pulmonary hypertension and heart failure.[2] It is chemically similar to
thiazide diuretics.[2] It works by decreasing insulin release from the
pancreas and increasing glucose release by the liver."
-
A new Alzheimer's drug brings hope,
controversy - CBS Sunday Morning, 11/28/21
-
Aduhelm, priced at $56,000 a year, is a key factor driving up Medicare
premiums - CNN, 11/16/21
|
|
